Table 2.
Baseline treatment, overall and according to CKD stage
| Treatment | Overall(N = 2542) |
CKD stage |
Pvaluea | |||
|---|---|---|---|---|---|---|
| ≤3A(n = 464) | 3B(n = 954) | 4(n = 1025) | 5(n = 99) | |||
| LLT, n (%) | ||||||
| Statin | 1476 (58) | 237 (51) | 564 (59) | 615 (60) | 60 (61) | 0.004 |
| Fibrate | 77 (3) | 23 (5) | 23 (2) | 29 (3) | 2 (2) | 0.06 |
| Bile acid sequestrants | 3 (0.1) | 0 | 3 (0.3) | 0 | 0 | 0.5 |
| Ezetimibe | 231 (9) | 47 (10) | 80 (8) | 96 (9) | 8 (8) | 0.7 |
| Omega 3 fatty acids | 30 (1) | 7 (2) | 12 (1) | 11 (1) | 0 | 0.3 |
| Classes of LLT, n (%) | ||||||
| None | 940 (37) | 194 (42) | 346 (36) | 364 (36) | 36 (36) | |
| Monotherapy | 1393 (55) | 227 (49) | 537 (56) | 573 (56) | 56 (57) | |
| Statin | 1272 (50) | 196 (42) | 495 (52) | 528 (52) | 53 (54) | |
| Ezetimibe | 44 (2) | 9 (2) | 17 (2) | 17 (2) | 1 (1) | |
| Fibrate | 70 (3) | 21 (5) | 21 (2) | 26 (3) | 2 (2) | |
| Bile acid sequestrant | 2 (0.1) | 0 | 2 (0.2) | 0 | 0 | |
| Omega 3 fatty acid | 5 (0.2) | 1 (0.2) | 2 (0.2) | 2 (0.2) | 0 | |
| Double therapy | 203 (8) | 42 (9) | 68 (7) | 86 (8) | 7 (7) | |
| Statin + ezetimibe | 180 (7) | 36 (8) | 60 (6) | 77 (8) | 7 (7) | |
CKD, chronic kidney disease; LLT, lipid-lowering treatment.
a
LLT use by CKD stage was compared using the Cochran-Armitage trend P value for binary variables.